Monash University has identified cyclic peptides acting as melanocortin MC5 receptor (MC5R) agonists reported to be useful for the treatment of diabetes, obesity, cardiomyopathy, heart failure, renal disorders, Rabson Mendenhall syndrome, Donohue syndrome and lipodystrophy.

Linkcure Therapeutics has synthesized molecular glue degraders acting as zinc finger protein 803 (ZNF803; WIZ) degradation inducers reported to be useful for the treatment of sickle cell anemia and β-thalassemia.

Hanmi Pharmaceutical Co. Ltd. has disclosed polypeptides acting as triple agonists of glucagon like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and glucose-dependent insulinotropic receptor (GDIR; GPR119) reported to be useful for the treatment of dyslipidemia.

Jiangsu Deyuan Pharmaceutical Co. Ltd. has described cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of hypertension.

SK Biopharmaceuticals Co. Ltd. has divulged GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified TNF-α inhibitors reported to be useful for the treatment of autoimmune diseases.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, cardiometabolic syndrome, cardiovascular disorders, Parkinson’s disease and Alzheimer’s disease.

Hangzhou Polymed Biopharmaceuticals Inc. has disclosed proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to an EGFR del19/Thr790Met/Cys797Ser triple mutant and/or EGFR Leu858Arg/Thr790Met/Cys797Ser triple mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.

Shanghai Huilun Pharmaceutical Co. Ltd. has described compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression.

Nxera Pharma UK Ltd. has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).